

5-Minute Journal Club: Defining the Future Role of TROP2-Directed Antibody-Drug Conjugates in Non-Small Cell Lung Cancer — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Datopotamab deruxtecan (Dato-DXd) recently received accelerated approval from the FDA for which indication?**
 - a. Previously untreated EGFR wild-type metastatic non-small cell lung cancer (mNSCLC)
 - b. EGFR wild-type mNSCLC previously treated with platinum chemotherapy
 - c. Previously untreated EGFR-mutant mNSCLC
 - d. EGFR-mutant mNSCLC previously treated with an EGFR-directed therapy and platinum-based chemotherapy
2. **Which of the following adverse events is most commonly reported among patients receiving Dato-DXd?**
 - a. Interstitial lung disease
 - b. Mucositis/stomatitis
 - c. LVEF (left ventricular ejection fraction) reduction
 - d. Acute kidney injury
 - e. Neutropenia
3. **Which of the following measures is appropriate for preventing or mitigating ophthalmic adverse events with Dato-DXd?**
 - a. Lubricating eyedrops
 - b. Ophthalmic assessment
 - c. Dose delay, dose reduction or discontinuation
 - d. All of the above
 - e. None of the above
4. **Which of the following statements best characterizes the intracranial activity of Dato-DXd in the Phase II TROPION-Lung05 study for patients with advanced or metastatic NSCLC with actionable genomic alterations who experienced disease progression on or after targeted therapy and platinum-based chemotherapy?**
 - a. No responses were observed
 - b. Responses were observed only in patients with baseline brain metastases
 - c. Responses were observed only in patients without baseline brain metastases
 - d. Responses were observed in patients with and without baseline brain metastases
5. **Which of the following descriptions best characterizes the design of the TROPION-Lung07 study evaluating combination therapy with Dato-DXd?**
 - a. Phase I study of Dato-DXd and pembrolizumab for advanced or metastatic NSCLC without actionable genomic alterations and with $\geq 50\%$ PD-L1 expression
 - b. Phase II study of Dato-DXd and durvalumab for advanced or metastatic NSCLC without actionable genomic alterations and with $\geq 50\%$ PD-L1 expression
 - c. Phase III study evaluating Dato-DXd and pembrolizumab with or without chemotherapy versus pembrolizumab with chemotherapy for advanced or metastatic NSCLC without actionable genomic alterations and with $< 50\%$ PD-L1 expression